Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Abbott Diabetes Care, Inc.
WARNING LETTER
•Abbott Diabetes Care, Inc.•October 23, 2025

Abbott Diabetes Care, Inc. – FDA Warning Letter, Oct 23, 2025

Record Details

The FDA issued a Warning Letter to Abbott Diabetes Care, Inc. on January 23, 2026, following an inspection from October 14 to October 23, 2025. The inspection found that the company"s FreeStyle Libre Flash and Continuous Glucose Monitoring Systems, including the FreeStyle Libre 3, were in violation of the Quality System Regulation (21 CFR Part 820) and specific controls for integrated continuous glucose monitoring (iCGM) devices, rendering them adulterated under the Federal Food, Drug, and Cosmetic Act.

Key violations include the failure to adequately establish procedures for design transfer, specifically concerning the translation of performance specifications, such as sensor glucose accuracy, to third-party manufacturers. The FDA also cited the company for not properly establishing finished device acceptance procedures, noting that fully assembled, sterilized, and packaged devices were released without final accuracy performance testing. Furthermore, Abbott failed to implement statistically valid techniques for acceptance criteria and sampling plans, and inadequately validated its manufacturing and release controls to ensure ongoing accuracy performance.

The FDA deemed Abbott"s responses to the inspection observations inadequate, indicating that proposed interim measures were not validated or sufficiently comprehensive. Abbott Diabetes Care, Inc. is required to take prompt action to correct these systemic violations. They must submit a written response to the FDA within fifteen business days detailing the specific corrective actions taken, including documentation and a timeline for completion, to prevent recurrence. Failure to adequately address these issues could lead to further regulatory actions, including injunctions, seizures, and civil penalties.

Company
Abbott Diabetes Care, Inc.
Inspection date
October 23, 2025
Product type
Devices
Office
Center for Devices and Radiological Health
People
  • Denise Reid
  • Christopher Scoggins
  • Barbara A. Marsden (Acting Director)
View Company Profile

ID · 265995f4-6db4-487c-a763-8c6c9cae68db

Violation Codes10
21 CFR 820.80(d)21 CFR 862.135521 CFR 820.250(a)21 CFR 820.30(h)21 CFR 82021 U.S.C. 321(h)21 CFR 862.1355(b)(1)(ii)21 U.S.C. 351(h)21 CFR 820.30(g)21 CFR 862.1355(b)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Abbott Diabetes Care, Inc.
  • 483 - 2025-10-23October 23, 2025
  • 483 - 2022-04-21April 21, 2022
  • 483 - 2017-12-04December 4, 2017
  • WARNING_LETTER - 2010-03-05March 5, 2010

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Abbott Diabetes Care, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.